Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q2 EPS by 5c; Guides FY11
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $248.36 +1.39%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q2 EPS of $0.82, $0.05 better than the analyst estimate of $0.77. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $61.86 million.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- XP Inc. (XP) Tops Q2 EPS by 8c
- InspireMD (NSPR) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
